Chemotherapy Induced Anemia-Pipeline Review, H1 2016

Chemotherapy Induced Anemia-Pipeline Review, H1 2016

  • Products Id :- GMDHC7737IDB
  • |
  • Pages: 66
  • |
  • |
  • |
  Request for Sample Report
  Request A Quote

Executive Summary


Global Markets Direct's, 'Chemotherapy Induced Anemia-Pipeline Review, H1 2016', provides an overview of the Chemotherapy Induced Anemia pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Chemotherapy Induced Anemia, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Chemotherapy Induced Anemia and features dormant and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.


The report provides a snapshot of the global therapeutic landscape of Chemotherapy Induced Anemia

The report reviews pipeline therapeutics for Chemotherapy Induced Anemia by companies and universities/research institutes based on information derived from company and industry-specific sources

The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

The report reviews key players involved Chemotherapy Induced Anemia therapeutics and enlists all their major and minor projects

The report assesses Chemotherapy Induced Anemia therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type

The report summarizes all the dormant and discontinued pipeline projects

The report reviews latest news related to pipeline therapeutics for Chemotherapy Induced Anemia

Reasons To Buy

Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

Identify and understand important and diverse types of therapeutics under development for Chemotherapy Induced Anemia

Identify potential new clients or partners in the target demographic

Develop strategic initiatives by understanding the focus areas of leading companies

Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics

Devise corrective measures for pipeline projects by understanding Chemotherapy Induced Anemia pipeline depth and focus of Indication therapeutics

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Read More

Contact Us:
Ken Research
Ankur Gupta, Head Marketing & Communications


Table of Contents

Table of Contents 2

List of Tables 5

List of Figures 5

Introduction 6

Global Markets Direct Report Coverage 6

Chemotherapy Induced Anemia Overview 7

Therapeutics Development 8

Pipeline Products for Chemotherapy Induced Anemia-Overview 8

Chemotherapy Induced Anemia-Therapeutics under Development by Companies 9

Chemotherapy Induced Anemia-Pipeline Products Glance 10

Late Stage Products 10

Clinical Stage Products 11

Early Stage Products 12

Chemotherapy Induced Anemia-Products under Development by Companies 13

Chemotherapy Induced Anemia-Companies Involved in Therapeutics Development 14

3SBio Inc. 14


Dr. Reddy's Laboratories Limited 16

Panacea Biotec Limited 17

Pfizer Inc. 18

Sandoz International GmbH 19

SBI Pharmaceuticals Co., Ltd. 20

Therapure Biopharma Inc. 21

Tolero Pharmaceuticals, Inc. 22

Vifor Pharma AG 23

Chemotherapy Induced Anemia-Therapeutics Assessment 24

Assessment by Monotherapy Products 24

Assessment by Combination Products 25

Assessment by Target 26

Assessment by Mechanism of Action 28

Assessment by Route of Administration 30

Assessment by Molecule Type 32

Drug Profiles 34

(aminolevulinic acid hydrochloride + sodium ferrous citrate)-Drug Profile 34

Product Description 34

Mechanism of Action 34

R&D Progress 34

darbepoetin alfa-Drug Profile 35

Product Description 35

Mechanism of Action 35

R&D Progress 35

darbepoetin alfa-Drug Profile 36

Product Description 36

Mechanism of Action 36

R&D Progress 36

darbepoetin alfa-Drug Profile 37

Product Description 37

Mechanism of Action 37

R&D Progress 37

darbepoetin alfa-Drug Profile 38

Product Description 38

Mechanism of Action 38

R&D Progress 38

epoetin alfa-Drug Profile 39

Product Description 39

Mechanism of Action 39

R&D Progress 39

epoetin zeta-Drug Profile 41

Product Description 41

Mechanism of Action 41

R&D Progress 41

ferric carboxymaltose-Drug Profile 43

Product Description 43

Mechanism of Action 43

R&D Progress 43

PRS-080-Drug Profile 45

Product Description 45

Mechanism of Action 45

R&D Progress 45

SSS-06-Drug Profile 47

Product Description 47

Mechanism of Action 47

R&D Progress 47

TBI-304H-Drug Profile 48

Product Description 48

Mechanism of Action 48

R&D Progress 48

TP-0184-Drug Profile 49

Product Description 49

Mechanism of Action 49

R&D Progress 49

TP-0413-Drug Profile 50

Product Description 50

Mechanism of Action 50

R&D Progress 50

TXA-302-Drug Profile 51

Product Description 51

Mechanism of Action 51

R&D Progress 51

Chemotherapy Induced Anemia-Recent Pipeline Updates 53

Chemotherapy Induced Anemia-Dormant Projects 58

Chemotherapy Induced Anemia-Discontinued Products 59

Chemotherapy Induced Anemia-Product Development Milestones 60

Featured News & Press Releases 60

Mar 11, 2015: Therapure Innovations Receives FDA Approval to Proceed with a Phase 1 Clinical Trial of Its Novel Anemia Therapeutic TBI 304H 60

Oct 30, 2012: SBI Pharmaceuticals Submits a Phase-1 Clinical Trial CTA to MHRA for a Drug to Treat Cancer Chemotherapy-induced Anemia 60

Apr 24, 2012: SBI Pharmaceuticals Announces Obtainment of Marketing Authorization of Products Containing 5-ALA from The Kingdom of Bahrain Ministry of Health 60

Oct 28, 2011: ALA Study Results Presented at the 49th Annual Meeting of Japan Society of Clinical Oncology 61

Oct 05, 2011: ALA Study Results Presented at Japanese Cancer Association, 70th Annual Meeting 61

Mar 18, 2011: Announcement of publication of ALA research in International Immunopharmacology 62

Sep 30, 2010: Safety study for subcutaneous epoetin alfa biosimilar Binocrit/Epoetin alfa Hexal/Abseamed suspended 62

Aug 09, 2010: Dr Reddy's Launches Darbepoetin Alfa For Treatment Of Anemia In India 63

Dec 01, 2008: International presentation of clinical safety and efficacy data for Binocrit, the world's first complex biosimilar 63

Jan 07, 2008: Sandoz and Gambro form strategic alliance 64

Appendix 65

Methodology 65

Coverage 65

Secondary Research 65

Primary Research 65

Expert Panel Validation 65

Contact Us 65

Disclaimer 66

List of Figures

Number of Products under Development for Chemotherapy Induced Anemia, H1 2016 8

Number of Products under Development by Companies, H1 2016 9

Comparative Analysis by Late Stage Development, H1 2016 10

Comparative Analysis by Clinical Stage Development, H1 2016 11

Assessment by Monotherapy Products, H1 2016 24

Number of Products by Targets, H1 2016 26

Number of Products by Stage and Targets, H1 2016 26

Number of Products by Mechanism of Actions, H1 2016 28

Number of Products by Stage and Mechanism of Actions, H1 2016 28

Number of Products by Routes of Administration, H1 2016 30

Number of Products by Stage and Routes of Administration, H1 2016 30

Number of Products by Molecule Types, H1 2016 32

Number of Products by Stage and Molecule Types, H1 2016 32

List of Tables

Number of Products under Development for Chemotherapy Induced Anemia, H1 2016 8

Number of Products under Development by Companies, H1 2016 9

Comparative Analysis by Late Stage Development, H1 2016 10

Comparative Analysis by Clinical Stage Development, H1 2016 11

Comparative Analysis by Early Stage Development, H1 2016 12

Products under Development by Companies, H1 2016 13

Chemotherapy Induced Anemia-Pipeline by 3SBio Inc., H1 2016 14

Chemotherapy Induced Anemia-Pipeline by BIOCAD, H1 2016 15

Chemotherapy Induced Anemia-Pipeline by Dr. Reddy's Laboratories Limited, H1 2016 16

Chemotherapy Induced Anemia-Pipeline by Panacea Biotec Limited, H1 2016 17

Chemotherapy Induced Anemia-Pipeline by Pfizer Inc., H1 2016 18

Chemotherapy Induced Anemia-Pipeline by Sandoz International GmbH, H1 2016 19

Chemotherapy Induced Anemia-Pipeline by SBI Pharmaceuticals Co., Ltd., H1 2016 20

Chemotherapy Induced Anemia-Pipeline by Therapure Biopharma Inc., H1 2016 21

Chemotherapy Induced Anemia-Pipeline by Tolero Pharmaceuticals, Inc., H1 2016 22

Chemotherapy Induced Anemia-Pipeline by Vifor Pharma AG, H1 2016 23

Assessment by Monotherapy Products, H1 2016 24

Assessment by Combination Products, H1 2016 25

Number of Products by Stage and Target, H1 2016 27

Number of Products by Stage and Mechanism of Action, H1 2016 29

Number of Products by Stage and Route of Administration, H1 2016 31

Number of Products by Stage and Molecule Type, H1 2016 33

Chemotherapy Induced Anemia Therapeutics-Recent Pipeline Updates, H1 2016 53

Chemotherapy Induced Anemia-Dormant Projects, H1 2016 58

Chemotherapy Induced Anemia-Discontinued Products, H1 2016 59

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License:
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

To know more information on Purchase by Section, please send a mail to sales [@]

3SBio Inc.


Dr. Reddy's Laboratories Limited

Panacea Biotec Limited

Pfizer Inc.

Sandoz International GmbH

SBI Pharmaceuticals Co., Ltd.

Therapure Biopharma Inc.

Tolero Pharmaceuticals, Inc.

Vifor Pharma AG

Chemotherapy Induced Anemia Therapeutic Products under Development, Key Players in Chemotherapy Induced Anemia Therapeutics, Chemotherapy Induced Anemia Pipeline Overview, Chemotherapy Induced Anemia Pipeline, Chemotherapy Induced Anemia Pipeline Assessment

select a license
Single User License
USD 2000 INR 144740
Site License
USD 4000 INR 289480
Corporate User License
USD 6000 INR 434220



I would like to thank Ken research team for meeting our report deliverables. The report is very good and we appreciate your well cooperation. ...

The research you conducted was very helpful for us and the integrity of your research approach gave us great confidence in the data. Look forward to collaborating again in future...

An excellent provider. Thorough, precise and outstanding insight. They drill down to what we need and their reports are effective at integrating text with supporting graphics and charts. Their reports are a great resource to go back too. ...

Coherent, high-quality, thoroughly-researched reports. We received a very quick response to all our queries which eventually expedited the entire process....

Well structured, the insights they shared with us were very helpful and reliable. Their timely assistance make their services invaluable to us. I would highly recommend them and would definitely use them again in the future if needed...

Ken Research Private Limited, Unit 14, Tower B3, Spaze I Tech Business Park, Sohna Road, sector 49
     Gurgaon, Haryana - 122001, India


Company Brochure

Engage with Us

sales [@]